| human | Q5 |
| P496 | ORCID iD | 0000-0003-3434-703X |
| P1053 | ResearcherID | R-9784-2018 |
| P69 | educated at | University of Graz | Q622683 |
| Medical University of Graz | Q872543 | ||
| Francisco Josephinum | Q1442047 | ||
| P108 | employer | University of California, Davis | Q129421 |
| Medical University of Graz | Q872543 | ||
| P734 | family name | Holzer | Q56243676 |
| Holzer | Q56243676 | ||
| Holzer | Q56243676 | ||
| P735 | given name | Michael | Q4927524 |
| Michael | Q4927524 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q91865991 | Abnormal composition and function of high-density lipoproteins in atopic dermatitis patients |
| Q55173997 | Advanced oxidation protein products are antagonists of the HDL receptor SR-BI |
| Q92658804 | Allergic rhinitis is associated with complex alterations in high-density lipoprotein composition and function |
| Q34259215 | Anti-psoriatic therapy recovers high-density lipoprotein composition and function |
| Q36681220 | Antipsoriatic treatment extends beyond the skin: recovering of high-density lipoprotein function |
| Q91148236 | Comment on Mathew et al. Therapeutic Lifestyle Changes Improve HDL Function by Inhibiting Myeloperoxidase-Mediated Oxidation in Patients With Metabolic Syndrome. Diabetes Care 2018;41:2431-2437 |
| Q35567375 | Cyanate is a novel inducer of endothelial icam-1 expression |
| Q36003077 | Dialysis Modalities and HDL Composition and Function |
| Q55420511 | HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients. |
| Q47144623 | HDL structure and function is profoundly affected when stored frozen in the absence of cryoprotectants |
| Q64764525 | Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairmen |
| Q38068018 | Inflammation alters HDL composition and function: implications for HDL-raising therapies |
| Q64071287 | Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humans |
| Q82343790 | Microwave-assisted high-throughput acid hydrolysis in silicon carbide microtiter platforms--a rapid and low volume sample preparation technique for total amino acid analysis in proteins and peptides |
| Q42931336 | Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein |
| Q36032978 | Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo |
| Q36050583 | Protein carbamylation renders high-density lipoprotein dysfunctional |
| Q36520321 | Psoriasis alters HDL composition and cholesterol efflux capacity |
| Q37472192 | Refined purification strategy for reliable proteomic profiling of HDL2/3: Impact on proteomic complexity. |
| Q41387814 | Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation |
| Q49889189 | The complex high-density lipoprotein proteome: a matter of purification? |
| Q34178582 | The myeloperoxidase product hypochlorous acid generates irreversible high-density lipoprotein receptor inhibitors |
| Q42025075 | The urea decomposition product cyanate promotes endothelial dysfunction |
| Q26827400 | Understanding high-density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology |
| Q45913726 | Uremia alters HDL composition and cholesterol efflux capacity. |
| Q35210194 | Uremia alters HDL composition and function |
Search more.